Previous studies have shown that expression of SMAD4 SNP or TGF-βR2/SMAD4 tumor protein in relation to the TGF-β pathway in pancreatic cancer can be utilized in clinical trials of targeted therapies [17]. This evidence concerns the gene TGFBR2 and familial pancreatic carcinoma.